< Back to: Dashboard

 

Immunotherapy

Everolimus for Cancer With TSC1 or TSC2 Mutation   In this research study, the investigators are evaluating the clinical benefit of everolimus in cancer patients with inactivating TSC1 or TSC2 mutations or activating MTOR mutations. This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called everolimus to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is being studied.
More Details...

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants This Phase Ib/II study is designed to assess the safety, tolerability, pharmacokinetics, immunogenicity, patient reported outcomes (PROs), and preliminary anti-tumor activity of atezolizumab administered by intravenous (IV) infusion alone or in combination with intravesical BCG in high-risk NMIBC participants.
More Details...

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC   Instiladrin (rAd-IFN/Syn3) is a non-replicating adenovirus vector harboring the human IFN alpha2b gene. When combined with the excipient Syn3, intravesical administration of the rAd-IFN results in transduction of the virus into the epithelial cell lining in the bladder. The IFN alpha2b gene is incorporated into the cellular DNA resulting in the synthesis and expression of l
More Details...

Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) The purpose of this trial is to assess the ability of CVA21, either alone (Part A) or in combination with pembrolizumab (Part B), to reach and to replicate in existing tumors (while sparing normal cells) and to establish a safe multi-dose schedule of the virus for the treatment of solid tumors where enhanced expression of ICAM-1 and/ or D
More Details...

Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to
More Details...

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing To test the safety and effectiveness of AdHER2 vaccination.
More Details...

Genetic Predictors of Benefit to Pembrolizumab   The primary objectives are to determine if tumor genetics (non-synonymous mutation burden > 200 mutations and mutational smoking signature [transversion high]) can predict durable clinical benefit (DCB) to pembrolizumab. The secondary objective is to determine if a combined genetic and immune (PD-L1, immune signature) analysis can predict durable clinic benefit better than either test alone. Our exploratory objectives are to identify a
More Details...

IMvigor 010 Study:  High Risk Muscle Invasive Bladder Cancer After Cystectomy A study to evaluate the efficacy and safety of adjuvant treatment with MPDL3280A, an anti-programmed death-ligand 1 (PD-L1) antibody, compared with observation in participants with PD-L1-selected muscle-invasive bladder cancer (MIBC) who are at high risk for recurrence following cystectomy. This study is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with observation in participa
More Details...

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure (BOND2) To study the safety and efficacy of CG0070, an oncolytic virus expression GMCSF in high grade non muscle invasive bladder cancer patients who do not respond to BCG therapy and refuse cystectomy.
More Details...

Phase 1 Study of MEDI4736 in Combination With Tremelimumab This Phase 1 study will evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with Tremelimumab in patients with advanced solid tumors.  
More Details...